Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
New FLAURA2 data confirm that adding chemotherapy to osimertinib improves survival outcomes in EGFR-mutated advanced lung cancer, regardless of whether patients carry a TP53 co-mutation. While TP53 mutations were a bad prognostic sign overall, the combo still outperformed osimertinib alone in both groups. The findings also suggest the combination may help overcome resistance driven by EGFR signal bypass alterations.
An exploratory analysis of the phase 3 FLAURA2 trial, presented at the IASLC 2026 World Conference on Lung Cancer, digs deeper into how baseline genetic co-mutations affect outcomes in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The big takeaway: adding platinum-pemetrexed chemotherapy to osimertinib (Tagrisso) numerically improved both progression-free survival (PFS) and overall survival (OS) over osimertinib alone — no matter what the patient's TP53 status was.
TP53 co-mutations, found in 67% of baseline plasma samples, were a negative prognostic marker across both treatment arms. But the combo still delivered a meaningful edge. Notably, EGFR signal bypass pathway alterations — the most common non-TP53 co-alterations — were linked to worse outcomes on osimertinib alone, but that disadvantage largely disappeared when chemotherapy was added, suggesting the combination may help overcome this form of intrinsic resistance.
By the Numbers:
Why it matters: These findings reinforce the clinical value of the osimertinib-chemotherapy combination across a broad range of patients, including those with high-risk TP53 co-mutations. For oncologists, the data also offer early signals about which resistance mechanisms may be less likely to emerge with combination therapy — potentially informing future treatment sequencing strategies.
